Scynexis (SCYX) Profit After Tax (2013 - 2026)
Scynexis' (SCYX) quarterly Profit After Tax came in at $7.4 million in Q2 2026, up 207.44% on a YoY basis from $2.4 million in Q2 2025, and up 134.73% quarter-over-quarter from -$21.3 million in Q1 2026.
Analysis
Scynexis (SCYX) Profit After Tax (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Profit After Tax for 14 consecutive years, with $7.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Profit After Tax rose 207.44% year-over-year to $7.4 million; the trailing twelve-month figure through Jun 2026 stood at -$10.2 million (up 47.56% YoY), and the FY2025 full-year result was -$8.6 million, up 59.56% from the prior year.
- Profit After Tax climbed to $7.4 million in Q2 2026 per SCYX's latest filing, from -$21.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at $122.3 million in Q2 2023 and bottomed at -$33.9 million in Q1 2023.
- Historically, Profit After Tax has averaged -$2.2 million across 5 years, with a median of -$6.2 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 4789.92% in 2022, then jumped 1016.15% in 2023.
- Over 5 years, Profit After Tax stood at -$14.4 million in 2022, then tumbled by 35.74% to -$19.6 million in 2023, then surged by 77.37% to -$4.4 million in 2024, then surged by 376.52% to $12.3 million in 2025, then sank by 39.66% to $7.4 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $7.4 million, -$21.3 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 7.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.40 Mn |
| Mar 31, 2026 | -21.30 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | -4.43 Mn |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | -19.59 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -14.43 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -5.45 Mn |
| Dec 31, 2021 | -29.28 Mn |
| Sep 30, 2021 | -605,000.00 |